AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05989815 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle damage protocol training
Description: The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
Study NCT05989815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle damage protocol training
Description: The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
Study NCT05989815 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation therapy (PBMT)
Description: PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
Study NCT05989815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Description: PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
Study NCT04128072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: • Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
Study NCT04128072 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Skin Electron Beam Therapy (TSEB)
Description: * After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration.
Study NCT04128072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (subsequent cycles post TSEB)
Description: • Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion.
Study NCT06336447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group #1: Virtual Reality Headset
Description: Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
Study NCT06336447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 No Virtual Reality Headset
Description: Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
Study NCT06246136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ELIOS
Description: Following cataract surgery, surgeon will proceed to ELIOS treatment.
Study NCT06246136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor Device
Description: Following cataract surgery, surgeon will proceed to Competitor treatment.
Study NCT04673630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Single dose subcutaneous injection
Study NCT05036434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab / Lenvatinib
Description: Pembrolizumab Plus Lenvatinib administration.
Study NCT04688710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Hypnosis (HYP)
Description: Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed ...) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels.
Study NCT04688710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation (MM)
Description: Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing.
Study NCT05273138 — intervention group
Intervention type: OTHER
Intervention: Blood sampling and skin biopsy
Description: Blood sampling and skin biopsy
Study NCT05356247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lausanne Trialogue Play Brief
Description: The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
Study NCT05670990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine assisted therapy
Description: A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group.
Study NCT06117644 — intervention group
Intervention type: DRUG
Intervention: Furmonertinib
Description: Furmonertinib 40 mg/tablet, 4 tablets, QD
Study NCT06348862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to either Quran, Music, and or Natural sound
Description: Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
Study NCT05520944 — intervention group
Intervention type: DRUG
Intervention: ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
Description: Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
Study NCT06261320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
Description: 4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
Study NCT04606316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given as intravenous (IV) infusion into a vein.
Study NCT04606316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab-Placebo
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
Study NCT04606316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given as intravenous (IV) infusion into a vein.
Study NCT05357274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic testing
Description: Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
Study NCT05404373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia (NBO)
Description: NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
Study NCT05404373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low flow oxygen
Description: immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
Study NCT04833049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994 Oral Tablet
Description: TAK-994 tablet.
Study NCT04833049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-994 Intravenous Infusion
Description: \[14C\]TAK-994 intravenous infusion.
Study NCT04606316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
Study NCT06009887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
Study NCT05474313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP-3D package
Description: A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
Study NCT04833049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-994 Oral Suspension
Description: \[14C\]TAK-994 oral suspension.
Study NCT05258565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV tPA (Activase)
Description: Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
Study NCT05474313 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Participants are given local standard of care navigation for initiation of PrEP
Study NCT04960332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
Study NCT05827562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+
Study NCT05589233 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccionation eighter started or full course
Description: Vaccination against SARS-CoV-2 at any number of doses
Study NCT04987957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
Study NCT04779476 — intervention group
Intervention type: OTHER
Intervention: Socket Dressing
Description: Following dental extraction immediately, the socket will be dressed with one of the materials tested
Study NCT05488327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
Study NCT06186089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: probiotics
Description: patients undergoing total gastrectomy take probiotics qd for 3 months
Study NCT04828928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electromyogram
Description: Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
Study NCT06133231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Description: Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
Study NCT06340269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEX-CD1 Dialysis
Description: MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit.
Study NCT05681923 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
Study NCT05681923 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection
Description: urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
Study NCT05681923 — intervention group
Intervention type: OTHER
Intervention: Neurodevelopmental assessment visit
Description: High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals.
Study NCT05681923 — intervention group
Intervention type: OTHER
Intervention: DNA collection
Description: If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
Study NCT05837221 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic sequencing
Description: Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
Study NCT05837221 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic analysis
Description: Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
Study NCT06026605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX212A
Description: WTX212A infusion once every 21 days
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Intravenous (IV) infusion
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous (IV) infusion
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Intravenous (IV) infusion
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous (IV) infusion
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemtuzumab Ozogamicin
Description: Intravenous (IV) infusion
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Intravenous (IV) infusion
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Intravenous (IV) infusion or subcutaneous injection
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous (IV) infusion or subcutaneous injection
Study NCT05183035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally via tablet or powder suspension
Study NCT05837767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).
Study NCT05837767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice Radiation Therapy
Description: A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
Study NCT05369429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Wellbeing Guide
Description: The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
Study NCT06547489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zelquistinel
Description: Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Study NCT06547489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zelquistinel
Description: Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Study NCT04862949 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab plus bevacizumab
Description: Atezolizumab plus bevacizumab
Study NCT05536492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
Study NCT05536492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALLOGRAFT
Description: EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
Study NCT05208086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of monoclonal component
Description: Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.